We are live on
!
Find out more
SCM
Sterling Capital Management Portfolio holdings
AUM
$5.9B
1-Year Est. Return
29.63%
This Fund
S&P 500
This Quarter
Est. Return
-1.56%
1 Year Est. Return
+29.63%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.45B
AUM Growth
-$851M
(-12%)
Cap. Flow
-$617M
Cap. Flow
% of AUM
-9.57%
Top 10 Holdings %
Top 10 Hldgs %
23.85%
Holding
3,274
New
30
Increased
484
Reduced
2,296
Closed
55
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$102M |
| 2 |
Accenture
ACN
|
+$72.7M |
| 3 |
Rockwell Automation
ROK
|
+$41.1M |
| 4 |
Booz Allen Hamilton
BAH
|
+$27.4M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$13.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Raymond James Financial
RJF
|
+$97M |
| 2 |
Hershey
HSY
|
+$93.2M |
| 3 |
Microchip Technology
MCHP
|
+$92.3M |
| 4 |
Global Payments
GPN
|
+$29.9M |
| 5 |
Merck
MRK
|
+$29.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.55% |
| 2 | Financials | 17.86% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 9.07% |
| 5 | Consumer Discretionary | 8.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Arrowhead Research
ARWR
$9.98B
| $1.55K | ﹤0.01% |
122
| – | – |
|
2602
Lyell Immunopharma
LYEL
$267M
| $1.55K | ﹤0.01% |
144
-129
| -47% | -$1.58K |
|
2603
Arhaus
ARHS
$1.04B
| $1.55K | ﹤0.01% |
178
-119
| -40% | -$1.27K |
|
|
CBLL
2604
CeriBell Inc
CBLL
$961M
| $1.54K | ﹤0.01% |
80
-55
| -41% | -$1.22K |
|
2605
Twin Disc
TWIN
$360M
| $1.52K | ﹤0.01% |
201
-178
| -47% | -$1.73K |
|
2606
Rigel Pharmaceuticals
RIGL
$829M
| $1.51K | ﹤0.01% |
84
-57
| -40% | -$1.16K |
|
2607
Phreesia
PHR
$642M
| $1.51K | ﹤0.01% |
59
| – | – |
|
2608
Ingevity
NGVT
$2.33B
| $1.5K | ﹤0.01% |
38
| – | – |
|
|
AVDX
2609
DELISTED
AvidXchange
AVDX
| $1.5K | ﹤0.01% |
177
| – | – |
|
|
PLL
2610
DELISTED
Piedmont Lithium
PLL
| $1.5K | ﹤0.01% |
238
-208
| -47% | -$1.66K |
|
2611
Savara
SVRA
$1.08B
| $1.5K | ﹤0.01% |
540
-319
| -37% | -$881 |
|
2612
Puma Biotechnology
PBYI
$477M
| $1.5K | ﹤0.01% |
505
-421
| -45% | -$1.32K |
|
2613
Rocky Brands
RCKY
$321M
| $1.49K | ﹤0.01% |
86
-74
| -46% | -$1.61K |
|
2614
GoPro
GPRO
$272M
| $1.49K | ﹤0.01% |
2,249
-2,002
| -47% | -$1.77K |
|
2615
IES Holdings
IESC
$12.4B
| $1.49K | ﹤0.01% |
18
+2
| +13% | +$209 |
|
2616
IDEAYA Biosciences
IDYA
$3.63B
| $1.47K | ﹤0.01% |
90
+5
| +6% | +$107 |
|
|
APGE
2617
DELISTED
Apogee Therapeutics
APGE
| $1.46K | ﹤0.01% |
39
| – | – |
|
|
RAPP
2618
Rapport Therapeutics
RAPP
$2.05B
| $1.45K | ﹤0.01% |
145
+2
| +1% | +$26 |
|
|
RGLS
2619
DELISTED
Regulus Therapeutics
RGLS
| $1.45K | ﹤0.01% |
830
-788
| -49% | -$1.04K |
|
|
IRBT
2620
DELISTED
iRobot
IRBT
| $1.45K | ﹤0.01% |
537
-374
| -41% | -$2.7K |
|
2621
OneSpan
OSPN
$657M
| $1.43K | ﹤0.01% |
94
-55
| -37% | -$979 |
|
|
SEZL
2622
Sezzle
SEZL
$4.01B
| $1.43K | ﹤0.01% |
41
-19
| -32% | -$805 |
|
2623
Korro Bio
KRRO
$207M
| $1.43K | ﹤0.01% |
82
-64
| -44% | -$1.9K |
|
2624
Fate Therapeutics
FATE
$282M
| $1.42K | ﹤0.01% |
1,799
-1,601
| -47% | -$1.96K |
|
2625
LifeMD
LFMD
$164M
| $1.42K | ﹤0.01% |
261
-209
| -44% | -$1.19K |
|
Similar funds
SM
DGI
GAM
CDDEC
AAS
DCP
SDIC
MSRPS
Sterling Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Sterling Capital Management held 3,274 positions worth $6.45B, down 12% from $7.3B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Sterling Capital Management withdrew a net $617M in Q1 2025, closing 55 positions and reducing 2,296 holdings. Its most notable exit was WESCO International, Inc. Depositary Shares each representing 1/1,000th interest in a share of Series A Fixed-Rate Reset Cumulative Perpetual Preferred Stock, an estimated $4.77M position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Sterling Capital Management opened a new position in Samsara worth $2.79M.
- Sterling Capital Management's largest Q1 2025 buy was Samsara: 72,827 shares worth $2.79M.
- Sterling Capital Management added most to Linde in Q1 2025, an estimated $102M increase.
- Sterling Capital Management's biggest Q1 2025 reduction was Raymond James Financial, cutting an estimated $97M.
- Sterling Capital Management fully exited WESCO International, Inc. Depositary Shares each representing 1/1,000th interest in a share of Series A Fixed-Rate Reset Cumulative Perpetual Preferred Stock in Q1 2025, selling an estimated $4.77M.
- Sterling Capital Management's ten largest holdings make up 24% of its $6.45B portfolio in Q1 2025.
- Sterling Capital Management opened 30 new positions and closed 55 in Q1 2025.
- Sterling Capital Management's portfolio value fell 12% quarter-over-quarter to $6.45B.
Based on Sterling Capital Management's 13F filing for Q1 2025, filed 13 May 2025.